Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;42(4):286-300.
doi: 10.4274/balkanmedj.galenos.2025.2025-4-69.

Generative Artificial Intelligence in Prostate Cancer Imaging

Affiliations
Review

Generative Artificial Intelligence in Prostate Cancer Imaging

Fahmida Haque et al. Balkan Med J. .

Abstract

Prostate cancer (PCa) is the second most common cancer in men and has a significant health and social burden, necessitating advances in early detection, prognosis, and treatment strategies. Improvement in medical imaging has significantly impacted early PCa detection, characterization, and treatment planning. However, with an increasing number of patients with PCa and comparatively fewer PCa imaging experts, interpreting large numbers of imaging data is burdensome, time-consuming, and prone to variability among experts. With the revolutionary advances of artificial intelligence (AI) in medical imaging, image interpretation tasks are becoming easier and exhibit the potential to reduce the workload on physicians. Generative AI (GenAI) is a recently popular sub-domain of AI that creates new data instances, often to resemble patterns and characteristics of the real data. This new field of AI has shown significant potential for generating synthetic medical images with diverse and clinically relevant information. In this narrative review, we discuss the basic concepts of GenAI and cover the recent application of GenAI in the PCa imaging domain. This review will help the readers understand where the PCa research community stands in terms of various medical image applications like generating multi-modal synthetic images, image quality improvement, PCa detection, classification, and digital pathology image generation. We also address the current safety concerns, limitations, and challenges of GenAI for technical and clinical adaptation, as well as the limitations of current literature, potential solutions, and future directions with GenAI for the PCa community.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Overview of GenAI and its application in PCa medical imaging. (Figure 1 was created and licensed using BioRender.com). GenAI, generative AI; CT, computed tomography; MRI, magnetic resonance image; GANs, generative adversarial networks; VAEs, variational autoencoders; PCa, prostate cancer.
Figure 2
Figure 2
Overview of key generative frameworks and their simplified structures as schematics. (Figure 2 was created and licensed using BioRender.com). GAN, generative adversarial network; VAE, variational autoencoder
Figure 3
Figure 3
Application of GenAI in medical image generation (a) synthetic CT image generation from real MR images, image source62 (b) synthetic AC-PET image generation from NAC-PET image, image source76 (c) synthetic hematoxylin and eosin (H&E) stained histology image of PCa generation from phosphatase and tensin homolog (PTEN) expressed immunohistochemistry (IHC) images and vice versa (PTEN IHC generation from H&E images). GenAI, generative AI; CT, computed tomography; MR, magnetic resonance; AC-PET, attenuation-corrected-positron emission tomography; NAC-PET, non-attenuation-corrected- positron emission emission tomography, PCa, prostate cancer.

Similar articles

References

    1. American Cancer Society. Cancer Facts & Figures 2025. In: The American Cancer Society Medical and Editorial Content Team, editor. Atlanta:American Cancer Society.2025.
    1. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi: 10.1038/s41572-020-00243-0. - DOI - PubMed
    1. Cereser L, Evangelista L, Giannarini G, Girometti R. Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer. Diagnostics (Basel) 2023;13(16):2697. doi: 10.3390/diagnostics13162697. - DOI - PMC - PubMed
    1. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. - DOI - PMC - PubMed
    1. Gravestock P, Shaw M, Veeratterapillay R, Heer R. Prostate cancer diagnosis: biopsy approaches. In: Barber N, Ali A, editors. Urologic Cancers. Brisbane (AU).2022. - PubMed

MeSH terms

LinkOut - more resources